In this discussion, our guests explore how recent regulatory changes are shaping the future of AI in drug development in the US market. Watch now.
Register to watch
In this discussion, our guests explore how recent regulatory changes are shaping the future of AI in drug development in the US market. We will also discuss the ripple effect these changes are having on a global scale. Our guests will provide their insights from investor, regulatory and legal perspectives to unpack the latest changes to guidance and communications their impacts on market and development strategies, cross-border collaboration, and legal frameworks.
Key Topics:
- Recent regulatory updates on AI in healthcare and drug development
- Implications for cross-border collaboration and U.S.–European alignment
- Judicial and compliance trends shaping the future of AI innovation
- Strategies for bringing AI solutions to market under evolving regulations
Panelists
Anne Elise Herold Li
Partner | Crowell & Moring LLP
Anne is the co-chair of Crowell & Moring’s Life Sciences and Patents groups, specializing in intellectual property for the biotech and pharma industries. As a first-chair trial lawyer, she employs innovative strategies to represent clients with groundbreaking products, aiming for favorable business resolutions or leveraging litigation for optimal outcomes. Anne excels in navigating complex legal issues, particularly in high-stakes litigations involving life sciences technologies, including cell and gene therapy, often securing key early victories that lead to advantageous settlements. Her expertise includes providing practical advice on patents, unfair competition, and trade secrets, tailored to the unique needs of clients ranging from biotech startups to large pharmaceutical firms. Anne is committed to understanding her clients’ businesses to develop bespoke strategies that align with their risk tolerance and business objectives. Her approach is informed by her deep industry knowledge and dedication to building long-term relationships with in-house counsel. Her focus has included artificial intelligence and its uses in the life sciences industry.
Sahir Ali
Founder & General Partner | Modi Ventures
Sahir Ali is an entrepreneur, technology and healthcare leader, investor, and board advisor with extensive experience in Artificial Intelligence, medical imaging, cancer research, enterprise technology, and cloud computing. He has advised and led some of the world’s largest companies and organizations in implementing and integrating cutting-edge technologies and data science practices. He is the founder and general partner of Modi Ventures.
Eli Weinberg
Partner | Bain & Company
Eli is an advisor and thought partner to life science innovators in biopharma, diagnostics, and medtech, as well as investors active in those areas. He is keenly interested in commercialization, value creation, new product modalities, applications of digital and analytics, and design. Eli has more than two decades of experience in the life sciences, spanning academia, biotech, and consulting.
